[Surgical treatment for hypertrophic obstructive cardiomyopathy: a report of 118 cases]

Ming-yao Luo1, Shui-yun Wang, Yun-hu Song

  • 1State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China.

Insights

Transaortic extended septal myectomy is a safe and effective surgical treatment for hypertrophic obstructive cardiomyopathy (HOCM), significantly relieving left ventricular outflow tract (LVOT) obstruction and improving patient symptoms and survival.

Area of Science:

  • Cardiovascular Surgery
  • Cardiology
  • Thoracic Surgery

Context:

  • Hypertrophic obstructive cardiomyopathy (HOCM) presents a significant clinical challenge.
  • Left ventricular outflow tract (LVOT) obstruction is a primary cause of symptoms and morbidity in HOCM patients.
  • Surgical intervention, specifically septal myectomy, is a key treatment modality.

Purpose:

  • To evaluate the clinical outcomes, including early and midterm survival, of transaortic extended septal myectomy in patients with HOCM.
  • To assess the efficacy of the extended Morrow's procedure in relieving LVOT obstruction and improving functional status.
  • To analyze the safety profile and complication rates associated with the surgical procedure.

Summary:

  • A retrospective analysis of 118 consecutive HOCM patients undergoing transaortic extended septal myectomy (Morrow's procedure) was conducted.
  • The procedure demonstrated a low in-hospital mortality (0.8%) and significant reductions in LVOT gradient and New York Heart Association (NYHA) class.
  • Midterm follow-up revealed no deaths or readmissions, with all patients experiencing improved physical ability and sustained NYHA class I-II.

Impact:

  • Transaortic extended septal myectomy offers a safe and highly efficacious treatment option for HOCM.
  • The surgical intervention effectively alleviates LVOT obstruction, leading to substantial symptomatic improvement and enhanced quality of life.
  • This procedure contributes to favorable early and midterm survival rates in patients with hypertrophic obstructive cardiomyopathy.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...